Xencor Inc — Form 8-K
Filed October 26, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Xencor presented Phase 1 data for XmAb819 (ENPP3 x CD3 bispecific) in advanced clear cell renal cell carcinoma (ccRCC) as of September 1, 2026. Across 68 expansion-dose patients (100, 200, 400 mcg/kg), confirmed objective response rates were 30%, 44%, and 45.5% respectively; 400 mcg/kg achieved 82% 6-month PFS Kaplan-Meier estimate. Company selected 400 mcg/kg IV as proposed Phase 3 dose and plans to discuss accelerated approval pathway with FDA in 1H2027, with registration-enabling study initiation targeted by end of 2027. Global randomized trial versus tivozanib control is planned for post-PD-(L)1 and VEGFR-TKI patients.
Why this rating
Material clinical milestone for ~$556M company—successful Phase 1 dose selection in solid tumors with meaningful efficacy (45% ORR vs benchmarks ~18-23%), manageable toxicity, and clear late-stage path planned for 2027. Third major XmAb program advancing; real value inflection point.
See more from October 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.